Thomson Reuters/Uni...
Health Care: Drugs
Novogen Ltd. (NVGN: NASDAQ)
$4.04 -0.05 | -1.22%
05/17/13 - 03:59 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 2.51M | 2.16M | 8.42M | 9.00M |
| Cost of Sales | 0.00 | 0.00 | 1.72M | 1.81M |
| Gross Operating Profit | 2.51M | 2.16M | 6.71M | 7.19M |
| Selling, General, and Administrative Expenses | 5.93M | 10.22M | 12.60M | 10.96M |
| Research & Development | 5.53M | 4.17M | 6.88M | 15.16M |
| Operating Income before D & A (EBITDA) | -8.95M | -12.23M | -12.77M | -18.94M |
| Depreciation & Amortization | 25.60K | 88.71K | 168.27K | 227.59K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 0.00 | 547.21K | 5.95K | -21.79K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -8.98M | -11.77M | -12.94M | -19.19M |
| Interest Expense | 0.00 | 19.24K | 12.75K | 8.88K |
| Pre-Tax Income | -8.98M | -11.79M | -12.95M | -19.20M |
| Income Taxes | 0.00 | 1.07K | 8.50K | 807.00 |
| Minority Interest | -2.72M | -3.19M | -2.47M | -3.92M |
| Net Income From Continuing Operations | -8.95M | -11.70M | -12.96M | 0.00 |
| Net Income From Discontinued Operations | 7.57M | 1.57M | 0.00 | 0.00 |
| Net Income From Total Operations | -1.38M | -10.13M | -12.96M | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 1.34M | -6.94M | -10.49M | -15.28M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-8.95M | -11.70M | -12.96M | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -8.95M | -11.70M | -12.96M | 0.00 |
| Basic EPS from Continuing Ops. | -1.51 | -2.08 | -2.57 | -3.75 |
| Basic EPS from Discontinued Ops. | 1.84 | 0.37 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.33 | -1.71 | -2.57 | -3.75 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.33 | -1.71 | -2.57 | -3.75 |
| Basic Normalized Net Income/Share | -1.51 | -2.08 | -2.57 | n.a. |
| EPS fr Continuing Ops. | -1.51 | -2.08 | -2.57 | -3.75 |
| EPS fr Discontinued Ops | 1.84 | 0.37 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.33 | -1.71 | -2.57 | -3.75 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.33 | -1.71 | -2.57 | -3.75 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.51 | -2.08 | -2.57 | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with NVGN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserSUPRATRADE HOT STOCKS (BUY ...
- User©SUPRATRADE HOT STOCKS (...
- Userscjs4r speculative
Latest NVGN Headlines from TheStreet
- 5 Stocks Poised to Break Out 05.10.13 | 02:05 pm
- Tiny Biotechs Dancing in the Bull Pen 05.20.09 | 12:05 pm
- Monday's Health Winners & Losers 09.18.06 | 03:09 pm
- Friday's Health Winners & Losers 08.25.06 | 03:08 pm
- Health Stocks in Motion 07.06.04 | 05:07 pm
Press Releases for NVGN
- As Released On 30 December, 2011: Novogen Modifies ADR Program And Makes Further Investment Into Marshall Edwards - PR Newswire 01.04.12 | 05:01 pm
- Glycotex, Inc. Awarded Cash Grant Under The U.S. Government Qualifying Therapeutic Discovery Program - PR Newswire 11.24.10 | 08:11 am
- Marshall Edwards Reaches Agreement In Principle To Acquire Intellectual Property Portfolio From Novogen - PR Newswire 09.08.10 | 08:09 am
- Marshall Edwards To Host Conference Call On September 8, 2010 - PR Newswire 08.31.10 | 09:08 am
- Marshall Edwards Appoints Oncologist Christine White To Board Of Directors - PR Newswire 08.10.10 | 07:08 am
Partner Headlines for NVGN
- Morning Market Movers - Benzinga 04.03.13 | 09:04 am
- On January 3rd, Novogen to Change ADR Conversion Ratio, Similar to a 5:1 Reverse Stock Split - Benzinga 12.29.11 | 01:12 pm
- Top Buy and Sell Ideas Based on Wednesday's Biggest Gainers - Seeking Alpha 07.28.11 | 09:07 am
